05/07/2023

Arecor Announces Additional Agreement with Leading Biopharmaceutical Company

Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has entered into an agreement with a leading biopharmaceutical company to support the ongoing development of a biosimilar product.

This revenue-generating collaboration follows an earlier technology partnership between the two companies, utilising Arecor’s proprietary technology platform, Arestat™, and formulation expertise. 

Sarah Howell, Chief Executive Officer of Arecor, said: “This collaboration demonstrates the strength of our know-how and expertise and the value that expertise can bring to our partners’ research programmes. We’re delighted to be working again with an existing partner, strengthening a key relationship and building on our track record of partnerships with leading biopharmaceutical and biotechnology companies.” 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR) 

 

Article source: arecor.com
Published: 05/07/2023